COMPLICATIONS IN NEUROLOGICAL PATIENTS AND STROKE PREVENTION

Gulomitdinov Sanjar; Rasulova Nilufar; Aminova Amalia

doi:10.5281/zenodo.10630842

Gulomitdinov Sanjar, Rasulova Nilufar, Aminova Amalia

Abstract. One of the most pressing problems is recognized in modern medicine and counseling. This is not surprising, since the population of almost all countries of the world is rapidly aging, and the overall impact of the risk factor on an individual is increasing. Statistics reflect the full scale of the problems; Thus, Russia ranks second in the world in terms of the consequences of death from stroke, ahead of all European countries and the United States. In addition, stroke and these indications lead to disability of the patient are dangerous. The seriousness of the clinical situation resulted in a disruption of the blood supply to the brain and bleeding with a deterioration in the state of health and glucose in the body

Keywords: complications, neurological, patient, prevention, stroke

References:

1. 1.Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management 2. of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893-962. doi:10.1093/ejcts/ezw313. 3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 2007;146:857-67. 4. Sulimov VA, Blagova OV, Galjavich AS, et al. Diagnosis and treatment of atrial fibrillation. Recommendations of the RKO, VNOA and the AAS. Moscow, 2012. р.92 (In Russ). Сулимов В. А., Благова О. В., Галявич А. С. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Москва, 2012. р. 92. 5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. doi:10.1056/NEJMoa1009638. 6. Patel MR, Mahaffey KW, Garg J, et al. The ROCKET AF Steering Committee for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. doi:10.1056/NEJMoa1009638. 7. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. doi:10.1056/NEJMoa1107039. 8. Connolly SJ, Eikelboom J, Joyner С, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17. doi:10.1056/NEJMoa1007432.